Drug Profile


Alternative Names: COL-144; LY-573144

Latest Information Update: 22 May 2017

Price : $50

At a glance

  • Originator Eli Lilly; Lundbeck A/S
  • Developer CoLucid Pharmaceuticals
  • Class Antimigraines; Benzamides; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Serotonin 1F receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Migraine

Most Recent Events

  • 12 Jun 2017 Eli Lilly plans a phase I trial in Healthy volunteers in USA (NCT03182920)
  • 06 May 2017 CoLucid Pharmaceuticals completes a phase I pharmacokinetics trial in Healthy volunteers in USA (PO, Liquid) (NCT03040362)
  • 20 Apr 2017 Phase-I clinical trials in Migraine (In volunteers) in USA (PO, Liquid) (NCT03040362)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top